USA based Boston Scientific is set to acquire Switzerland based Symetis for $435 million. The all-cash deal is expected to close in second quarter of 2017 after customary closing conditions are met.
Symetis specializes in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.
Symetis is a medical technology company that engages in the development, manufacturing, and marketing of transcatheter aortic valve implantation (TAVI) devices for minimally invasive heart valve replacement.
Symetis was founded in 2001 and is headquartered in Ecublens, Switzerland.
About Boston Scientific
Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg.
Boston Scientific was founded in 1979 and is headquartered in Marlborough, Massachusetts, USA.
Source: – Symentis’s Press Release